GET THE APP

Non-Small Cell Lung Cancer | Open Access Journals
Cancer Science & Therapy

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Non-Small Cell Lung Cancer

Lung cancer features a poor prognosis; over half people diagnosed with carcinoma die within one year of diagnosis and therefore the 5-year survival is a smaller amount than 18%. Non-small cell carcinoma (NSCLC) accounts for the bulk of all carcinoma cases. Risk factors for developing NSCLC are identified, with cigarette smoking being a serious factor alongside other environmental and genetic risk factors. Depending on the staging of carcinoma, patients are eligible surely treatments starting from surgery to radiation to chemotherapy also as targeted therapy. With the advancement of genetics and biomarkers testing, specific mutations are identified to raised target treatment for individual patients. Lung cancer is among the deadliest cancers for both men and women. Its death rate exceeds that of the three commonest cancers (colon, breast, and pancreatic) combined. Over half patients diagnosed with carcinoma die within one year of diagnosis and therefore the 5-year survival is around 17.8%.

 

There are two main subtypes of carcinoma, small-cell lung carcinoma and non-small-cell lung carcinoma (NSCLC), accounting for 15% and 85% of all carcinoma, respectively.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Google Scholar citation report
Citations: 5332

Cancer Science & Therapy received 5332 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward